Landmark examples are the detection of T790M mutation in NSCLC treated with anti-EGFR[41], the early detection of emergence of KRAS mutations in colorectal cancer[42] and the detection of mutations reverting sensitivity to PARP-inhibitors in prostate cancer[43]. This evidence concerns the gene KRAS and colorectal cancer.